I’m excited for the speed in which weight-loss grows for $HIMS because it sucks subscribers into an ecosystem they won’t want to leave. Hormonal treatment + Peptides will be the next massive verticals!

$HIMS WE'RE BACK!!!!

$HIMS is trading 50% below June 24 2025 closing price, a day after $NVO terminated the initial partnership. $HIMS has officially launched Wegovy today, after reuniting with $NVO. The stock makes no sense. The company is doing great.

The non-linear $HIMS thesis is materialising as I expected. I believe $HIMS intrinsic value is $2,000/share by 2030. Peptides are a non-linear wealth creation event and $HIMS has quietly manoeuvred its way into being uniquely positioned to capitalise on it.

BREAKING $HIMS $30 PT| BUY Rating🚀🚀🚀 Canaccord's analyst Maria Ripps reiterated $HIMS Buy Rating and maintained $30 Price Target. "Hims & Hers officially launched access to Wegovy (oral and injectable) and Ozempic injections across all dosage levels on its platform, marking

invest in biotech now invest in longevity now invest in peptides now invest in personalized medicine now invest in the acceleration of biology now thank you for your attention to this matter future/acc.

🚨 BREAKING: THE FDA HAD A 6-HOUR MEETING TODAY TO DISCUSS DIETARY SUPPLEMENTS PEPTIDES WERE MENTIONED 36 TIMES 👀 $HIMS $LLY $NVO h/t ThePeptideList

Why am I hearing so many of my friends and co workers talking about agentmaxxing all of a sudden… Probably nothing.

📌

🚨 BREAKING: RO AT #4 APP STORE MEDICAL CATEGORY $HIMS AT #16 (UP FROM #18 LAST WEEK) HERS AT #17 (UP FROM #24 LAST WEEK)

$HIMS - HOT PEPTIDE SUMMER LOADING

For years, progress in healthcare has lagged behind technological innovation – leading to fragmented, reactive systems that are stuck in the past. That’s about to change. Hear from CTO Mo Elshenawy about how we’ve built AI as the operating system for care, empowering customers

Basically everything happening around $HIMS points to an incoming ChatGPT moment for healthcare, of which $HIMS is going to be the primary beneficiary. Any other scaled healthcare startup is valued at $10B, while investors continue to cry about $HIMS for no reason.

If you think AI film can’t be art then explain this.

$HIMS two years ago: Share price: $19 Revenue (annual): $872M Net income: $1.2M Adj EBITDA: $20.6M Subscribers: 1.2M $HIMS right now: Share price: $19 Revenue (annual): $2.35B (+170% in two years) Net income: $128M Adj EBITDA: $318M Subscribers: +2.5M And no more lawsuit + Novo

🚨 BREAKING: $HIMS CEO ANDREW DUDUM SAYS HE WANTS TO SPONSOR THE WORLD CUP "The FIFA World Cup brought to you by Hims & Hers" ?!? 🔥🔥🔥